Ineke E. Hamming

Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial

Ninke Leffers, Annechien J.A. Lambeck, Marloes J.M. Gooden et al. · International Journal of Cancer · 2009 · 141 citations

Medicine, Immunology, Oncology +17

Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer

Ninke Leffers, Renee Vermeij, Baukje‐Nynke Hoogeboom et al. · International Journal of Cancer · 2011 · 60 citations

Medicine, Immunology, Oncology +17

Distinct regulation and impact of type 1 T‐cell immunity against HPV16 L1, E2 and E6 antigens during HPV16‐induced cervical infection and neoplasia

Mariëtte I.E. van Poelgeest, Esther R. Nijhuis, Kitty M.C. Kwappenberg et al. · International Journal of Cancer · 2005 · 48 citations

Medicine, Immunology, Pathology +17

P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy

Annechien J.A. Lambeck, Ninke Leffers, Baukje‐Nynke Hoogeboom et al. · International Journal of Cancer · 2007 · 35 citations · Full text

Life Sciences, Immunology, Oncology +17

Potentiation of a P53-SLP vaccine by cyclophosphamide in ovarian cancer, A single ARM phase II study

Renee Vermeij, Ninke Leffers, Baukje‐Nynke Hoogeboom et al. · Data Archiving and Networked Services (DANS) · 2011 · 31 citations

Medicine, Immunology, Oncology +17